Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized multicenter study of lutikizumab versus adalimumab in moderate to severe active ulcerative colitis
MOH_2024-04-16_013378Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutikizumab in autoimmune colitis (3 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and Change in disease activity. Started Apr 2024; status: completed.
02
Drugs
lutikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2024-04-16_013378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-16_013378.